IFNA1 and systemic lupus erythematosus: After observing 238 SLE patients for 24 weeks, it was found that although the primary and secondary endpoints were not reached, rontalizumab performed well in patients with low IFN signal measurements (ISMs), which was unexpected in terms of improving disease activity, reducing flares, and steroid reduction (81, 82).